Section 232 Pharma 100 Percent T-0 First Day: What Annex III Filings Look Like on July 31 2026

At 12:01 AM Eastern Time on July 31 2026, the first tranche of the Section 232 patented pharmaceutical tariff took effect. Only the 17 pharmaceutical companies specifically named in Annex III of the April 2 proclamation are affected at this effective date. Every other importer of covered products sees the same 100 percent duty on September 29 2026, 60 days from now.

This is the T-0 operational rundown.

The proclamation structure in one paragraph

The April 2 2026 presidential proclamation "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States" created a tiered Section 232 duty framework on patented pharmaceutical products, associated active pharmaceutical ingredients (APIs), and key starting materials. Annex I enumerates the HTS scope across Chapters 29 (organic chemicals) and 30 (pharmaceutical products). Annex II lists 13 companies with pre-April-2 most-favored-nation pricing agreements that are exempt from duty through January 20 2029. Annex III lists 17 named companies whose covered imports are hit at 100 percent starting July 31 2026. Annex IV lists specialty products (orphan drugs, cell and gene therapies, nuclear medicines, plasma therapies, fertility products, antibody drug conjugates, CBRN medical countermeasures, animal health products) that are carved out entirely.

The country-based rate tiers

The 100 percent headline rate is not universal. Country-of-origin tiers cut across the framework:

• Products of the European Union, Japan, South Korea, Switzerland, and Liechtenstein: 15 percent Section 232 rate
• Products of the United Kingdom: 10 percent Section 232 rate (with mechanism to fall to zero if a bilateral pricing agreement is executed)
• Companies operating under an approved onshoring plan: 20 percent Section 232 rate through April 30 2030, with the rate falling to zero if the company also executes an MFN pricing agreement with HHS
• Everyone else: 100 percent

The country tiers apply irrespective of Annex III listing. So a covered Annex III company importing an API from South Korea today faces 15 percent, not 100 percent. The tier is anchored on country of origin at the entry line, and the Annex III listing is anchored on the importer identity.

The exemption structure

Generics and biosimilars are carved out entirely. This is the critical read for anyone whose portfolio spans patented and generic products classified under the same HTS subheadings. The declaration at entry needs to identify patented versus generic status on the covered SKUs, backed by the FDA Orange Book or Purple Book listing for records-audit response.

US-origin pharmaceutical products, APIs, and key starting materials are also carved out. This includes formulations manufactured in the United States from imported bulk API where the substantial transformation test is met at the US finishing step.

Orphan-designated drugs are exempt across all approved indications. That means a drug that has an orphan designation for even one indication is exempt on all import lines, even if 90 percent of end-use is a non-orphan indication.

What the day-one filing environment looks like for the 17 Annex III importers

The operational read for the named companies is threefold:

First, classification. The Annex I HTS list needs to be cross-walked against the SKU master. Any SKU classified under an Annex I heading is presumed covered unless a specific exemption applies (patent status, orphan designation, country-of-origin tier).

Second, importer-of-record identity. The Annex III listing is per-legal-entity, not per corporate family. A parent company on Annex III may have subsidiaries or affiliates not named. Only imports where the Annex III entity is the importer of record on the entry summary are affected at the July 31 date. Imports made by non-listed affiliates hit the September 29 date instead.

Third, entry-line coding. Until the CBP CSMS bulletin lands with specific Chapter 99 filing instructions for the pharma layer, brokers are working off the proclamation text directly. Expect a heading in the 9903.02 or 9903.06 range (mirroring the metals derivative and forced-labor cluster) to serve as the collection mechanism, with an accompanying HTS-to-tier mapping table.

The stacking rule with other 2026 layers

The Section 232 pharma layer is additive to whatever the base HTSUS duty is plus any other Chapter 99 layers already applicable to the entry line.

Worked example. A covered API classified under 2941.90.10, imported by an Annex III company from India (not in the preferred-country tier), with no orphan designation and no generic exemption. On the same entry line:

• Base HTSUS duty for 2941.90.10: 0 percent (typical Chapter 29 API rate)
• Section 232 pharma layer: 100 percent
• Section 301 forced-labor layer (India is in the 60-economy list): 10 percent (India is in the 10 percent tier per the July 24 USTR final action)
• Section 122: 0 percent (sunset July 24)

Total layered duty rate: 110 percent on top of a base of 0 percent. On a 500,000 USD entry line, that is 550,000 USD in duty owed at the entry filing.

If the same line is imported from South Korea instead, the pharma layer drops to 15 percent, and the Section 301 forced-labor layer drops to zero (South Korea is not in the 60-economy list). Total layered duty: 15 percent. Entry-line duty on 500,000 USD becomes 75,000 USD.

The country-tier delta is that large. Substitution economics for Annex III companies with active supplier-diversification plays get a hard economic push today.

Finance and cash flow implications for Annex III companies

For a large pharma company with 500 million USD to 2 billion USD in annual covered imports, the day-one exposure delta is:

• 100 percent on non-preferred origin (typical for India, China, most non-EU/Japan/Korea sourcing) = 500 million to 2 billion USD annual additional duty
• 15 percent on EU/Japan/Korea/Swiss/Liechtenstein origin = 75 million to 300 million USD annual additional duty
• 0 percent on generic, orphan, US-origin, or Annex II MFN-agreement lines = zero delta

The finance-side reads are cash flow (customs bond sizing has to accommodate potentially 10x pre-July-31 duty levels), letter of credit terms (import LC sizing anchored on landed cost has to be re-worked), and pricing pass-through (PBM contract negotiation and Medicare Part B/D reimbursement cycles both have contract-locked prices that do not adjust instantly to a new duty layer).

For a mid-size specialty pharma importer under 100 million USD annual covered volume, the day-one exposure is proportionally smaller but the operational disruption is the same shape.

The MFN and onshoring deal offsets

Two paths cut the rate:

MFN pricing agreement with HHS. Companies that execute an MFN agreement gain duty exemption through January 20 2029 if they are on Annex II. Companies on Annex III can negotiate an MFN agreement to fall to zero on the additional 20 percent onshoring surcharge but not to eliminate the base 100 percent (the onshoring plan pathway is the mechanism for base rate reduction).

Onshoring plan. Companies with a Commerce-approved onshoring plan cut the rate to 20 percent through April 30 2030. Onshoring plans require Commerce approval against forthcoming Federal Register criteria (not yet published as of the effective date). Companies without an approved plan pay 100 percent.

The regulatory calendar to watch: Commerce publication of onshoring plan approval criteria, HHS MFN agreement template publication, and any Annex III revisions in the Federal Register (companies can be added or removed by proclamation amendment).

The T-0 through T+7 monitoring pattern for affected importers

Pull the entry summary log for the first week of July 31 through August 6 for every covered subheading. Flag each entry line by: (a) which company legal entity was the importer of record, (b) which Annex tier applied, (c) which country-of-origin rate tier applied, (d) whether an exemption was claimed and on what basis. That is the operational baseline for defending the filings during records-audit demands.

CBP records demands under 19 USC 1509 on the pharma lines will start landing in Q4 2026 and Q1 2027 for high-value entries filed in the first 60 days. The importers with clean documentary chains (patent status certificates, orphan designation confirmations, MFN agreement copies, onshoring plan approval letters, country-of-origin substantial transformation documentation) will process the demands cleanly. The importers with paper-only exemption claims will absorb the 100 percent duty via post-summary correction with liquidated damages exposure.

The read for non-Annex-III importers over the next 60 days

If your company is not on Annex III, you have 60 days to complete:

• Full SKU cross-walk against Annex I HTS scope
• Country-of-origin restructuring decisions on any high-volume non-preferred-tier lane
• MFN or onshoring negotiation with HHS and Commerce respectively
• Broker software configuration and Chapter 99 filing workflow setup
• Bond sizing review and cash flow forecast update
• Customer contract price pass-through language review

The 60-day window is not long for pharma supply chains that operate on 6 to 18 month qualification cycles for supplier substitution. The realistic scope for the window is administrative preparation (broker, bond, cash), not physical supply chain restructuring. That means the September 29 effective date will produce a duty absorption event for most non-Annex-III importers, with substitution and reshoring plays landing in 2027 and later.